CAMBRIDGE, Mass., March 8, 2019 /PRNewswire/ -- Leap Therapeutics,
Inc. (Nasdaq: LPTX), a biotechnology company focused on developing
targeted and immuno-oncology therapeutics, today announced the
Company will be presenting at the Society of Gynecologic Oncology
2019 Annual Meeting on Women's Cancer, being held March 16-19, 2019 in Honolulu, HI.
About the DKN-01 P204 clinical trial
The P204 study is a Phase 2 basket study of DKN-01 as both a
monotherapy and in combination with paclitaxel in patients with
advanced endometrioid unterine (EEC) and endometrioid ovarian (EOC)
cancers. These malignancies have a percentage of patients with
mutations in the Wnt pathway. The study consists of four dosing
groups and will enroll up to 94 patients using a Simon 2-Stage
design in each group. The primary objective in each independent
study group is to determine the overall response. Secondary
objectives include measures of efficacy such as overall survival
and progression free survival, and to evaluate the safety of the
treatment regimen.
Leap Presentation Details:
Abstract Number: 65
Title: Safety and efficacy of a DKK1
inhibitor (DKN-01) as monotherapy or in combination with paclitaxel
in patients with Wnt activated recurrent gynecologic
malignancies
Session Title: Oral Featured Poster Session II: Trials, Basic
Science and Translational Science
Date: Monday, March
18
Time: 6:00 – 7:00 PM GMT
Location: Hawaii Convention Center
313AB
About Leap Therapeutics
Leap Therapeutics
(Nasdaq:LPTX) is focused on developing targeted and immuno-oncology
therapeutics. Leap's most advanced clinical candidate, DKN-01, is a
humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein, a Wnt pathway modulator. DKN-01
is in clinical trials in patients with esophagogastric,
hepatobiliary, gynecologic, and prostate cancers. Leap's second
clinical candidate, TRX518, is a humanized GITR agonist monoclonal
antibody designed to enhance the immune system's anti-tumor
response that is in advanced solid tumor studies. For more
information about Leap Therapeutics, visit http://www.leaptx.com or
our public filings with the SEC that are available via EDGAR at
http://www.sec.gov or via https://www.leaptx.com/investors.
FORWARD LOOKING STATEMENTS
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, Section
21E of the Securities Exchange Act of 1934 and the Private
Securities Litigation Reform Act of 1995, which involve risks and
uncertainties. These statements include statements regarding Leap's
intended use of proceeds from the offering, Leap's expectations
with respect to the development and advancement of DKN-01, TRX518,
and other programs, including the initiation, timing and design of
future studies, enrollment in future studies, business development,
and other future expectations, plans and prospects. Leap has
attempted to identify forward looking statements by such
terminology as ''believes,'' ''estimates,'' ''anticipates,''
''expects,'' ''plans,'' ''projects,'' ''intends,'' ''may,''
''could,'' ''might,'' ''will,'' ''should,'' or other words that
convey uncertainty of future events or outcomes to identify these
forward-looking statements. Although Leap believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, forward-looking statements are
subject to known and unknown risks, uncertainties and other factors
that could cause actual results to differ materially from our
expectations. Such risks and uncertainties include, but are not
limited to: the accuracy of our estimates regarding expenses,
future revenues, capital requirements and needs for financing; the
ability to complete a financing or form business development
relationships to fund our expenses; the outcome, cost, and timing
of our product development activities and clinical trials; the
uncertain clinical development process, including the risk that
clinical trials may not have an effective design or generate
positive results; our ability to obtain and maintain regulatory
approval of our drug product candidates; our plans to research,
develop, and commercialize our drug product candidates; our ability
to achieve market acceptance of our drug product candidates;
unanticipated costs or delays in research, development, and
commercialization efforts; the applicability of clinical study
results to actual outcomes; the size and growth potential of the
markets for our drug product candidates; our ability to continue
obtaining and maintaining intellectual property protection for our
drug product candidates; and other risks. Detailed information
regarding factors that may cause actual results to differ
materially will be included in Leap Therapeutics' periodic filings
with the SEC, including Leap Therapeutics' Annual Report on Form
10-K for the fiscal year ended December 31,
2017 that Leap filed with the SEC on February 23, 2018 and Leap Therapeutics'
Quarterly Reports on Form 10-Q for each of the quarters ended
March 31, 2018, June 30, 2018 and September 30, 2018 that Leap filed with the SEC
on each of May 11, 2018, August 8, 2018 and November 9, 2018, respectively. These statements
are only predictions and involve known and unknown risks,
uncertainties, and other factors. Any forward looking statements
contained in this release speak only as of its date. We undertake
no obligation to update any forward-looking statements contained in
this release to reflect events or circumstances occurring after its
date or to reflect the occurrence of unanticipated events.
CONTACT:
Douglas E. Onsi
Chief Financial Officer
Leap Therapeutics, Inc.
donsi@leaptx.com
617-714-0360
Argot Partners
Investor Relations
Heather Savelle
212-600-1902
heather@argotpartners.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/leap-therapeutics-to-present-at-the-society-of-gynecologic-oncology-2019-annual-meeting-on-womens-cancer-300809077.html
SOURCE Leap Therapeutics, Inc.